Amyloidosis: Diagnosis
The question
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of trends in the level of provision of SAP scanning for amyloidosis diagnosis for patients; and what assessment he has made of potential challenges to accessing this diagnostic test.
Answered by Preet Kaur Gill
The Government is committed to improving the lives of those living with rare diseases, such as amyloidosis, under the UK Rare Diseases Framework. We published the fifth annual England action plan in February 2026, where we report on the steps we have taken to advance the priorities of the framework, including getting a diagnosis faster.
SAP scintigraphy for amyloidosis in England is a specialised service provided nationally by the National Amyloidosis Centre at the Royal Free London, under a Medicines and Healthcare products Regulatory Agency (MHRA) specials licence. The Department is aware that this service is currently paused while the MHRA undertakes a regulatory review, during which additional testing and assurance have been requested. The National Amyloidosis Centre is working with the MHRA to complete this work as quickly as possible with a view to restoring the service. During this period, clinicians are using alternative diagnostic pathways where clinically appropriate to support timely diagnosis and management of patients with suspected amyloidosis.
NHS England continues to monitor the position, including access and provision challenges arising from the pause, and will work to ensure that appropriate diagnostic testing is available to patients where clinically required.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →